Overview

A Study in Subjects With Retinitis Pigmentosa

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.
Phase:
Phase 2
Details
Lead Sponsor:
Aldeyra Therapeutics, Inc.